New Delhi: Covishield and Covaxin prices, Covid vaccines that are expected to immediately get regular market approval from Indian drug regulators, are likely to be limited to RS 275 per dose plus additional costs of Rs 150, the official source said.
According to them, the authority of the Determination of National Pharmacy (NPPA) has been directed to start working towards capping prices to make affordable vaccines.
Until now, Covaxin is priced at 1,200 rs per dosage while Covishield costs Rs 780 in private facilities.
Prices include RS 150 service fees.
Both vaccines are only authorized for emergency use in this country.
The Subject Expert Committee in Covid-19 Central Medicine Standard Control Organization on January 19 recommends providing regular market approval to Covid Covishield and Covaxin vaccines for use in certain conditions.
“NPPA has been asked to work to limit vaccine prices.
The price tends to be limited to Rs 275 per dose along with additional service costs of Rs 150,” the official source said.
Prakash Kumar Singh, Director (Government and Regulatory Affairs) in India Serum, has submitted a request to the drug controller General India on October 25, which seek regular market approval for covishiled vaccines.
A few weeks ago, V Krishna Mohan, all the time the director at Bharat Biotech, submitted complete information about chemistry, manufacturing and control, along with pre-clinical and clinical data while looking for regular market authorization for Covaxin.
Covaxin and Covishield were given an emergency use authorization (EUA) on January 3 last year.
Each covishield dose, Covaxin is likely to be limited to RS 275 after obtaining regular market approval
